Central Retinal Vein Occlusion Clinical Trial
Official title:
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.
The primary objective of SCORE2 is to test for non-inferiority based on mean change from baseline in visual acuity letter score at Month 6 for eyes randomized to intravitreal bevacizumab every 4 weeks compared with eyes randomized to intravitreal aflibercept every 4 weeks using a non-inferiority margin of 5 letters. Secondary objectives of SCORE2 are to: - compare the bevacizumab and the aflibercept groups with regards to central retinal thickness, as measured with spectral domain optical coherence tomography (SD-OCT), at Month 6 and change between baseline and Month 6; - assess Month 12 visual acuity and SD-OCT outcomes associated with different dosing strategies after Month 6 in participants who respond well to treatment; - assess Month 12 visual acuity and SD-OCT outcomes associated with alternative treatment strategies after Month 6 in participants who respond poorly to treatment; - compare area of retinal ischemia and rates of neovascular complications of CRVO in the bevacizumab vs. aflibercept groups; - add to our knowledge of the safety profile of these anti-vascular endothelial growth factor (VEGF) medications in the setting of eyes with macular edema secondary to CRVO; - conduct a cost effectiveness analysis comparing intravitreal bevacizumab to intravitreal aflibercept to assess the economic implications from a payor perspective using decision analytic methods. Other exploratory aims of SCORE2 are to: - investigate the correlation of features identified through SD-OCT segmentation analysis, such as the inner segment-outer segment (IS-OS) junction (also known as the ellipsoid zone), with such characteristics as visual acuity and central retinal thickness; - investigate the correlation of area of peripheral retinal nonperfusion from widefield fluorescein angiography with visual acuity and central retinal thickness, and the prognostic value of baseline peripheral and central retina perfusion status in predicting disease course and treatment responsiveness; - investigate the correlation of features on adaptive optics imaging with such characteristics as visual acuity and central retinal thickness. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT01231633 -
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
|
N/A | |
Terminated |
NCT00969293 -
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT03981549 -
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
|
Phase 1/Phase 2 | |
Completed |
NCT02274259 -
Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
|
Phase 4 | |
Completed |
NCT01360385 -
Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab
|
N/A | |
Not yet recruiting |
NCT00383773 -
Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion
|
N/A | |
Completed |
NCT00952614 -
A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
|
N/A | |
Recruiting |
NCT04601701 -
Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
|
N/A | |
Withdrawn |
NCT03417401 -
Surgical Stabilizer Assisted RVC With rtPA for CRVO
|
Phase 1 | |
Completed |
NCT01976312 -
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
|
Phase 3 | |
Completed |
NCT01724554 -
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
|
Phase 1/Phase 2 | |
Completed |
NCT01471691 -
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01011374 -
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT03223714 -
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
|
Phase 3 | |
Recruiting |
NCT01827722 -
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
|
Phase 4 | |
Completed |
NCT00906685 -
Bevacizumab for Central Retinal Vein Occlusion Study
|
Phase 3 | |
Active, not recruiting |
NCT04793100 -
Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections
|
N/A | |
Recruiting |
NCT02405741 -
Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients
|
Phase 2 | |
Recruiting |
NCT01348633 -
Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
|
N/A |